Overview of Vision and Objectives
MNC Email Signature
MNC FTP site
Internal Starter Grants
Core Facilities Grants
To MNC Faculty:We request your propositions for speakers in the Motor Neuron Center external seminar program.
Speakers: Researchers or clinicians working in the areas covered by the MNC and/or likely to interest a cross-section of MNC members
Time and place: 11:00 a.m., first Friday of each month, N.I. Auditorium (unless we are informed of major scheduling clashes)
MNC provides: Coach air travel, one night's hotel, dinner invitation, assistance with logistics (travel, scheduling of day at CU)
Please send propositions and, where appropriate, date constraints to: firstname.lastname@example.org
We would like your feedback on an initiative spearheaded by Brent Stockwell on behalf of the MNC, in potential collaboration with the Cancer and Genome Centers. The aim is to create a resource for lentiviral vectors expressing hairpin loop shRNAs for specific gene knockdown. This would allow MNC members much more easily to perform loss-of-function studies both in vitro and in vivo. Such studies could be focused on single genes, on functional groups of genes, or on genome-wide screens.
Thanks to unpublished work by Brent and many collaborators at Harvard and the Broad Institute, we potentially have access to large collections of lentiviral shRNAs. The plan is to target 15,000 genes for each genome (mouse and human) over 3 years (the group is about halfway into this period now and on target in terms of production). There will be 5 clones / gene, making 150,000 clones in total. As you know, the advantage of lentiviral vectors is their high efficacy and low toxicity in neuronal systems.
Since we have free access to this collection, the challenge is to set up a facility that would centralize production and handling of viral stocks for the whole university. The scale and cost of this operation will depend very much on the number of potential users and screens, as will the practical details of organization. It may also be possible in a second phase to extend this operation to a collection of full-length cDNAs in lentiviral vectors.
We need to come to a fairly rapid decision on MNC involvement in such a facility. If you are interested in being involved in further discussions, please send us a few sentences describing the use your lab would have for such a facility, with an indication of timeframe and number of clones/screens you anticipate using.
Brent (email@example.com) has offered to respond to any questions you have.
|Home Contact Us © Columbia University Center for Motor Neuron Biology and Disease|